Prummel M F, Wiersinga W M, Mourits M P, Koornneef L, Berghout A, van der Gaag R
Department of Endocrinology, Academic Medical Center, Amsterdam, The Netherlands.
Arch Intern Med. 1990 May;150(5):1098-101.
Many clinicians have the impression that treatment of thyroid dysfunction ameliorates ophthalmopathy in Graves' disease. The aim of our study was to relate thyroid function to the severity of Graves' ophthalmopathy. We studied 90 patients with Graves' ophthalmopathy and Graves' hyperthyroidism in whom severity of Graves' ophthalmopathy and thyroid function (regardless of antithyroid treatment) were assessed when referred to our institution. Patients were assigned to four groups (A through D) with increasingly severe Graves' ophthalmopathy using Total Eye Score based on the NOSPECS classification. The percentage of dysthyroid patients in each group was determined: group A had 23% dysthyroid patient (5); group B, 32% (9); group C, 61% (14); and group D, 47% (8). More dysthyroid patients were in the groups with severe Graves' ophthalmopathy. We also compared the severity of Graves' ophthalmopathy between euthyroid (n = 54) and dysthyroid (n = 36) patients: euthyroid patients had less proptosis (19.9 +/- 3.5 vs 20.8 +/- 3.4 mm), better visual acuity (0.93 +/- 0.17 vs 0.88 +/- 0.18), and lower Total Eye Score (8.6 +/- 6.6 vs 10.6 +/- 6.6). We conclude that dysthyroidism is associated with more severe Graves' ophthalmopathy. Our findings suggest that meticulous control of thyroid function also during antithyroid treatment is important in the management of Graves' ophthalmopathy.
许多临床医生认为,甲状腺功能障碍的治疗可改善格雷夫斯病的眼病。我们研究的目的是将甲状腺功能与格雷夫斯眼病的严重程度联系起来。我们研究了90例格雷夫斯眼病和格雷夫斯甲亢患者,在他们转诊至我们机构时评估了格雷夫斯眼病的严重程度和甲状腺功能(无论是否接受抗甲状腺治疗)。根据NOSPECS分类,使用全眼评分将患者分为四组(A至D组),格雷夫斯眼病的严重程度逐渐增加。确定了每组甲状腺功能异常患者的百分比:A组有23%的甲状腺功能异常患者(5例);B组为32%(9例);C组为61%(14例);D组为47%(8例)。甲状腺功能异常患者更多地集中在格雷夫斯眼病严重的组中。我们还比较了甲状腺功能正常(n = 54)和甲状腺功能异常(n = 36)患者之间格雷夫斯眼病的严重程度:甲状腺功能正常的患者眼球突出度较小(19.9±3.5 vs 20.8±3.4 mm),视力更好(0.93±0.17 vs 0.88±0.18),全眼评分更低(8.6±6.6 vs 10.6±6.6)。我们得出结论,甲状腺功能异常与更严重的格雷夫斯眼病相关。我们的研究结果表明,在抗甲状腺治疗期间,对甲状腺功能进行细致控制对格雷夫斯眼病的管理也很重要。